AI-Powered Gene Editing Innovator Metagenomi Files for IPO with Preclinical Platform Surpassing CRISPR-Cas9

Recently,Gene Editing Company Metagenomi to Go Public on Nasdaq, Raising Nearly $87 Million Through IPOMetagenomi is committed toBy utilizing differential gene editing system toolsBox to develop potential therapeutic treatments, accurately editing DNA where existing technologies fall short. Due to the capital winter, the enthusiasm of investors has waned, which willIt is one of the few preclinical gene-editing biotechnology companies to have gone public through an IPO in the past two years.

Gene editing is a revolutionary technology that enables the editing of target genes by knocking out or inserting specific DNA fragments. Since its inception, the CRISPR/Cas9 technology has demonstrated unparalleled advantages over other gene editing technologies and shown great potential in disease treatment, agricultural cultivation, microbial design, and other fields. However, with continuous in-depth research,Scientists have found that CRISPR/Cas9 has certain limitations, such as off-target effects and chromosomal translocations., Metagenomi's technology aims to break through these problems.

▲Metagenomi's Technology

(Image Source:Metagenomi Official Website）

The basic strategy of Metagenomi's gene editing discovery and development system isStarting with a large amount of metagenomic data, AI-based cloud computing was used to discover natural nucleases from microbial environments in nature, and a set of CRISPR-based gene editing tools was constructed accordingly.Metagenomi has tested hundreds of new gene editing tools and validated their utility in human therapeutics. The company has developedGene editing tools include the CRISPR gene editing system, ultra-compact base editing system, and CRISPR-associated transposase (CAST) system.This system can precisely insert large segments of DNA into the genome.

▲Metagenomi's Gene Editing Tools

(Image Source: Metagenomi Official Website)

Brian C. Thomas, CEO and founder of Metagenomi, is a scientist at the University of California, Berkeley, and one of the pioneering scientists in the field of metagenomics.Chief Scientist Luis Borges has previously worked at Amgen, Five Prime Therapeutics, Cell Medica, and Century Therapeutics.

The 4th International Symposium on Gene Editing and Gene Therapy Technology

• Discovery of Novel AAV Vectors and Capsid Engineering

• Enhancing Non-Liver Tissue-Specific Targeting Strategies

• Process Development and Clinical Application of Dual AAV Vectors

• The Innovative Path to Large-Scale Production of AAV Vectors

• Advances in Gene Therapy for Neurodegenerative Diseases

• Delivery Strategies for In Vivo Gene Editing Therapy

• Differentiated Innovation in Ophthalmic Gene Therapy

• Gene Therapy from Genetic Diseases to Metabolic Diseases

• Innovation in Gene Therapy Mediated by Novel Vectors

• AAV Vectors for Cancer Immunotherapy

• Efficient Targeted Insertion or Replacement of Large DNA Fragments

• Underlying Innovation and Safety of Gene Editing Tools

• The Application Prospects of Epigenetic Technology

999 piecesFree single tickets,

Limited Time Offer!

Collaboration, Speeches, Synchronously Recruiting

Unlike biotech companies that have already completed their IPOs this yearMetagenomi, although it has developed multiple highly efficient nucleases and several pipelines focused on in vivo gene editing, covering fields such as hemophilia, cystic fibrosis, cardiovascular diseases, oncology, and metabolic disorders, is still a platform-based company without any clinical-stage development projects.。

However, without clinical-stage pipelines, the reason this company can stand out among many biopharmaceutical enterprises during the biotech winter is:InUnder the endorsement of Metagenomi, Inc.,The Company's Pioneering Technology and Preclinical ResearchProvided a better prognosis。According to founder Brian Thomas,The nucleases they possess outperform the existing CRISPR-Cas9 gene editing system in terms of gene editing efficiency, with editing efficiency exceeding 90%, and some even surpassing 95%.

At the 2023 ASGCT conference, Metagenomi announced data on multiple nucleases it has developed. Among them,The novel V-shaped nuclease MG29-1 demonstrates high efficiency in editing primary human cells in the laboratory, reaching up to 75% in hepatocytes and approximately 70% across the entire liver.High editing efficiency was also observed in mice and non-human primates.

The olive branch extended to Metagenomi,

It is the favor of the leader and the real investment of capital.

 eMedClub

November 2021,Moderna Announces Strategic R&D Collaboration with Metagenomi to Combine Metagenomi's Novel CRISPR Gene Editing Tools with Moderna's Advanced mRNA Platform and Lipid Nanoparticle (LNP) Delivery Technology for the Development of Curative Therapies for Patients with Severe Genetic Disorders.Moderna stated that this collaboration aims to create new gene-editing tools, providing better tools for scientific research and clinical treatment.

Only a year later,Prominent Small Nucleic Acid Drug Company Ionis Pharmaceuticals Reaches Nearly $3 Billion Collaboration Agreement with MetagenomiAccording to reports, this collaboration is divided into two parts. The first part includes four gene targets, for which Ionis will pay an upfront fee of $80 million. Among these, two targets will be co-developed with Metagenomi. When the first of these four targets in the first part is submitted for clinical trials, Ionis will sign a collaboration agreement with Metagenomi for the second part, which includes another four targets, with an upfront payment of $120 million. The potential total transaction amount for all eight targets is close to $3 billion.

June 16, 2022,Metagenomi and Affini-T Therapeutics Announce Partnership to Develop Cell Therapies for Solid Tumors Using Metagenomi's Gene Editing TechnologyBy collaborating with Metagenomi, Affini-T will gain access to powerful new gene editing tools capable of precise and multiplexed modifications of immune cells, thereby optimizing the effector functions of its cell therapies.

Therefore, Metagenomi's successful IPO may be closely related to these collaborations, which also indirectly confirmsThe Unique Potential of Metagenomi's Metagenomics-Based Nucleases.

In addition to extensive collaborations with leading companies, Metagenomi has secured over $400 million in funding from more than 30 investment firms and pharmaceutical manufacturers since its establishment in 2018, including well-known enterprises such as Bayer, RA Capital, Moderna, Bristol Myers Squibb, SymBiosis, and Catalio Capital Management.In May 2021, Metagenomi announced the completion of its Series A+ financing, increasing the total Series A financing from US$65 million in November 2020 to US$75 million.In January 2023, Metagenomi announced the completion of a $100 million Series B expansion financing.Series B financing reached 275 million US dollars,This financing amount is already at the top level in the field of gene editing.Exceeded Prime Medicine founded by Liu Rupeng.It was revealed that the funds raised this time are aimed at advancing the clinical pipeline.Expand its gene-editing portfolio and initiate its first non-human primate study.

However,The main challenge at this stage still focuses on research and development. Advancing the product pipeline to the clinical stage is an important indicator of proven technology reliability.In addition,The development of in vivo gene editing is also remarkable, and new delivery technologies will become a crucial part.Current delivery methods, such as lipid nanoparticles (LNPs) and viral vectors, are not perfect and have significant shortcomings in terms of tissue tropism, immunogenicity, or long-term efficacy. As novel editing technologies and delivery methods continue to emerge, the market will naturally phase out approaches that prove ineffective or underperforming through the intense competition among innovative technology platforms.Promote self-optimization and screening in the gene editing field, and gene editing companies will also move towards a leaner and more refined model.。